PCVX (NASDAQ: PCVX) affiliate plans sale of 2,500 shares via option exercise

Rhea-AI Filing Summary

PCVX notice of proposed sale of 2,500 common shares via exercise of stock options on 03/11/2026. The filing lists shares outstanding of 143,920,361 as of 03/11/2026. It also records a prior sale of 11,623 shares on 12/23/2025 for $556,971.85.

Insights

Securities Compliance Analyst

Form 144 records a small option-derived sale and prior dispositions.

The filing documents an intended sale of 2,500 common shares by exercise of stock options on 03/11/2026. It identifies the method as cash and shows an issuer-side transaction type.

Shares outstanding are reported as 143,920,361 as of 03/11/2026, giving scale context; prior reported sale was 11,623 shares on 12/23/2025. Cash-flow treatment and any transfer restrictions are not detailed in the excerpt.

FAQ

What does PCVX's Form 144 report?

The filing reports a proposed sale of 2,500 common shares via exercise of stock options on 03/11/2026. It also lists prior sales of 11,623 shares on 12/23/2025 for $556,971.85.

Who appears to have sold shares in the prior transaction?

The excerpt attributes the prior sale to Elvia Cowan, showing 11,623 shares sold on 12/23/2025 for $556,971.85. The filing text supplies the seller name and sale amount.

How large is the proposed sale relative to outstanding shares for PCVX?

The proposed sale is 2,500 shares versus reported outstanding shares of 143,920,361 as of 03/11/2026. The filing provides these counts but does not compute percentages or dilution.

Does the Form 144 indicate who receives proceeds from the sale?

The excerpt shows the sale method as an exercise of stock options with cash indicated, but it does not explicitly state which party receives proceeds beyond the transaction method shown in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/11/2026 - 04:06 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001960048
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Vaxcyte, Inc.
SEC File Number	001-39323
Address of Issuer	825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CALIFORNIA 94070
Phone	650-837-0111
Name of Person for Whose Account the Securities are To Be Sold	Cowan Elvia
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc 11 Madison Ave 4th Floor New York NY 10010	2500	146550.00	143920361	03/11/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/11/2026	Exercise of stock options	Issuer			2500	03/11/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Elvia Cowan 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070	Common	12/23/2025	11623	556971.85

144: Remarks and Signature

Remarks
Date of Notice	03/11/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/08/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc, as attorney-in-fact for Elvia Cowan
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)